Dentsply Sirona announced on July 21, 2025, the appointment of Daniel Scavilla as President and Chief Executive Officer, effective August 1, 2025. Mr. Scavilla, a current member of the Board of Directors, succeeds Simon Campion, who will depart the company on July 31, 2025.
Mr. Scavilla brings over three decades of experience in the medical technology and pharmaceutical industries, most recently serving as President and CEO of Globus Medical, where he led the acquisition of NuVasive. His appointment is expected to accelerate the company's business transformation and reposition Dentsply Sirona as an industry leader.
In conjunction with the leadership transition, Dentsply Sirona also announced select preliminary financial results for the second quarter of 2025, expecting net sales of approximately $935 million and adjusted EPS between $0.50 and $0.52. The company reaffirmed its full-year 2025 outlook, maintaining its previous guidance for net sales and adjusted EPS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.